

# American College of Radiology ACR Appropriateness Criteria®

**Clinical Condition:** Primary Bone Tumors

**Variant 1:** Screening. First study.

Radiologic Procedure	Rating	Comments	RRL*
X-ray area of interest	9	This procedure is absolutely required in a patient with suspected bone lesion.	Varies
US area of interest	1		O
MRI area of interest without and with contrast	1		O
MRI area of interest without contrast	1		O
Tc-99m bone scan whole body	1		☼ ☼ ☼
CT area of interest without contrast	1		Varies
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
FDG-PET/CT whole body	1		☼ ☼ ☼ ☼
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 2:** Positive localized or regional symptoms. Radiographs negative or findings do not explain symptoms.

Radiologic Procedure	Rating	Comments	RRL*
MRI area of interest without contrast	9		O
MRI area of interest without and with contrast	7	See statement regarding contrast in text under "Anticipated Exceptions."	O
Tc-99m bone scan whole body	5	Perform this procedure if better localization is needed.	☼ ☼ ☼
CT area of interest without contrast	5	This procedure may be useful for certain types of tumors.	Varies
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
US area of interest	1		O
FDG-PET/CT whole body	1		☼ ☼ ☼ ☼
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition: Primary Bone Tumors****Variant 3: Lesion on radiographs definitively benign. Not osteoid osteoma.**

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
CT area of interest without contrast	4	Perform this procedure if the patient is symptomatic locally.	Varies
MRI area of interest without contrast	4	Perform this procedure if the patient is symptomatic locally.	O
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
US area of interest	1		O
MRI area of interest without and with contrast	1		O
Tc-99m bone scan whole body	1		☢ ☢ ☢
FDG-PET/CT whole body	1		☢ ☢ ☢ ☢
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 4: Lesion on radiographs. Radiographic and/or clinical pattern suspicious for osteoid osteoma.**

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
CT area of interest without contrast	9		Varies
MRI area of interest without and with contrast	6	Dynamic contrast enhancement may be valuable in this procedure. See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	5		O
Tc-99m bone scan whole body	4	SPECT might be useful as an adjunct to this procedure.	☢ ☢ ☢
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
US area of interest	1		O
FDG-PET/CT whole body	1		☢ ☢ ☢ ☢
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition: Primary Bone Tumors****Variant 5: Lesion on radiographs. Indeterminate for malignancy with mineralized matrix.**

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
MRI area of interest without and with contrast	8	See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	7		O
CT area of interest without contrast	7		Varies
Tc-99m bone scan whole body	5	This procedure may be helpful when evaluating for disease distribution or other areas of involvement.	☼ ☼ ☼
FDG-PET/CT whole body	3		☼ ☼ ☼ ☼
CT area of interest without and with contrast	2		Varies
CT area of interest with contrast	1		Varies
US area of interest	1		O
X-ray radiographic survey whole body	1		☼ ☼ ☼
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 6: Lesion on radiographs. Indeterminate for malignancy. Lytic lesion.**

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
MRI area of interest without and with contrast	8	See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	7		O
CT area of interest without contrast	7		Varies
X-ray radiographic survey whole body	5	Perform this procedure if there is concern that the lesion represents multiple myeloma.	☼ ☼ ☼
Tc-99m bone scan whole body	5	This procedure may be helpful when evaluating for disease distribution or other areas of involvement.	☼ ☼ ☼
CT area of interest without and with contrast	4	Perform this procedure if MRI is contraindicated.	Varies
FDG-PET/CT whole body	3		☼ ☼ ☼ ☼
CT area of interest with contrast	2		Varies
US area of interest	1		O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition:**      **Primary Bone Tumors****Variant 7:**                      **Lesion on radiographs. Indeterminate for malignancy. Sclerotic or mixed lytic/sclerotic lesion.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><a href="#"><u>RRL*</u></a></b>
MRI area of interest without and with contrast	8	See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	7		O
CT area of interest without contrast	7		Varies
Tc-99m bone scan whole body	5		☼ ☼ ☼
CT area of interest without and with contrast	4	Perform this procedure if MRI is contraindicated.	Varies
FDG-PET/CT whole body	3		☼ ☼ ☼ ☼
X-ray radiographic survey whole body	2		☼ ☼ ☼
CT area of interest with contrast	2		Varies
US area of interest	1		O
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>

**Variant 8:**                      **Lesion on radiographs. Aggressive, suspicious for malignancy.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><a href="#"><u>RRL*</u></a></b>
MRI area of interest without and with contrast	9	See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	8		O
CT area of interest without contrast	7	This procedure is especially useful for areas with complex osseous anatomy.	Varies
Tc-99m bone scan whole body	6	This procedure is particularly helpful to look for multifocal disease.	☼ ☼ ☼
X-ray radiographic survey whole body	5	Perform this procedure if there is concern that the lesion represents multiple myeloma.	☼ ☼ ☼
CT area of interest without and with contrast	5	Perform this procedure if MRI is contraindicated.	Varies
FDG-PET/CT whole body	5	This procedure is particularly helpful to look for multifocal disease.	☼ ☼ ☼ ☼
CT area of interest with contrast	2		Varies
US area of interest	1		O
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>

**Clinical Condition:** Primary Bone Tumors**Variant 9:** Lesion with pathological fracture on radiographs. Not definitively benign.

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
MRI area of interest without and with contrast	8	See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	7		O
CT area of interest without contrast	5		Varies
Tc-99m bone scan whole body	5	This procedure is particularly helpful to look for multifocal disease.	⚠ ⚠ ⚠
CT area of interest without and with contrast	4	Perform this procedure if MRI is contraindicated.	Varies
FDG-PET/CT whole body	4		⚠ ⚠ ⚠ ⚠
CT area of interest with contrast	2		Varies
US area of interest	1		O
X-ray radiographic survey whole body	1		⚠ ⚠ ⚠
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 10:** No radiographs. “Incidental” finding on MRI. Not clearly benign.

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
X-ray area of interest	9		Varies
MRI area of interest without and with contrast	5	Use of this procedure depends on size and location in addition to sequences and field of view on original MRI. See statement regarding contrast in text under “Anticipated Exceptions.”	O
MRI area of interest without contrast	5	Use of this procedure depends on size and location in addition to sequences and field of view on original MRI.	O
CT area of interest without contrast	5		Varies
FDG-PET/CT whole body	2		⚠ ⚠ ⚠ ⚠
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
Tc-99m bone scan whole body	1		⚠ ⚠ ⚠
US area of interest	1		O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition:**      Primary Bone Tumors

**Variant 11:**              No radiographs. “Incidental” finding on CT. Not clearly benign.

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
MRI area of interest without contrast	9		O
MRI area of interest without and with contrast	7	See statement regarding contrast in text under “Anticipated Exceptions.”	O
X-ray area of interest	5	Use of this procedure depends on size and location in addition to adequacy of initial CT evaluation.	Varies
Tc-99m bone scan whole body	4		☢ ☢ ☢
CT area of interest without contrast	3	Use of this procedure depends on the quality of the original CT. A focused study may be helpful in some cases.	Varies
CT area of interest with contrast	1		Varies
CT area of interest without and with contrast	1		Varies
FDG-PET/CT whole body	1		☢ ☢ ☢ ☢
US area of interest	1		O
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>

## PRIMARY BONE TUMORS

Expert Panel on Musculoskeletal Imaging: William B. Morrison, MD<sup>1</sup>; Barbara N. Weissman, MD<sup>2</sup>; Mark J. Kransdorf, MD<sup>3</sup>; Ronald Adler, MD, PhD<sup>4</sup>; Marc Appel, MD<sup>5</sup>; Stephanie A. Bernard, MD<sup>6</sup>; Michael A. Bruno, MD<sup>7</sup>; Ian Blair Fries, MD<sup>8</sup>; Isabelle Germano, MD<sup>9</sup>; Langston T. Holly, MD<sup>10</sup>; Timothy J. Mosher, MD<sup>11</sup>; Jeffrey J. Olson, MD<sup>12</sup>; Christopher J. Palestro, MD<sup>13</sup>; Catherine C. Roberts, MD<sup>14</sup>; Michael J. Tuite, MD<sup>15</sup>; Robert J. Ward, MD<sup>16</sup>; Adam C. Zoga, MD.<sup>17</sup>

### **Summary of Literature Review**

#### **Introduction/Background**

Numerous imaging techniques are available for evaluating bone tumors. However, radiographs remain the primary screening technique and are the least expensive methods of detecting and histologically characterizing many tumors or tumor-like conditions of bone [1]. When a classically nonaggressive lesion is detected on routine radiographs, additional studies may not be required unless surgical intervention is contemplated and further anatomic information is required. In this setting either computed tomography (CT) or magnetic resonance imaging (MRI) may be most appropriate for additional characterization and preoperative evaluation [1-3].

#### **Magnetic Resonance Imaging and Computed Tomography**

When radiographic features are indeterminate or the lesion is more aggressive and considered to be potentially malignant, additional imaging studies are frequently required. In the past, radionuclide imaging was used to evaluate bone lesions in this setting. However, today, because of the improved anatomic detail and sensitivity of MRI, it is preferred over radionuclide studies [4]. Early evaluation of MRI and CT demonstrated that MRI was superior for staging of bone tumors before treatment [1,3,5,6]. Zimmer et al [3] and Hogeboom et al [6] described MRI and CT features of bone tumors with regard to cortical destruction, marrow, soft-tissue, joint, and neurovascular involvement. Hogeboom et al [6] reported that MRI was superior to CT in detecting cortical bone destruction in 4.5% of patients studied, for marrow involvement in 25%, for soft-tissue involvement in 31%, for joint involvement in 36.4%, and for invasion of neurovascular structures in 15.3%. In the same categories, MRI and CT were felt to be equal in 63%–82% of patients. CT was superior to MRI in detecting cortical bone destruction in 13.6% of patients and neurovascular involvement in 7.7% [6]. However, Panicek et al [7] more recently showed no difference between CT and MRI for evaluation of extent of tumor involvement in 183 patients with primary bone tumors, suggesting that both are equally accurate for staging purposes. Comparison studies are not recent, and evolution of technology may limit relevance of these data.

In most institutions the imaging technique depends on patient status as well as the location and type of suspected lesion. MRI is most typically used for staging lesions in the extremities [1,3,5,8,9]. Intravenous contrast dye can be useful to determine vascularity of lesions [10-12], detect vascular invasion [13], and identify necrotic or cystic areas. MR spectroscopy has potential to differentiate benign from malignant lesions, but more research is needed [14,15]. CT is usually preferred when tumors are located within the periosteal or cortical regions, with flat bones with thin cortex and little marrow, as well as in small bones such as those in the hands and feet, in which case higher resolution can be advantageous. CT can better demonstrate tumor mineralization, which may be suspected or indeterminate on radiographs [16]. CT may also be preferred in certain circumstances where characterization of osseous anatomy and proximity to other structures is paramount, including pelvis and spine. For rib lesions, thin-section CT is useful to exclude fracture through a nonaggressive lesion [17] or to differentiate traumatic versus

<sup>1</sup>Principal Author, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. <sup>2</sup>Panel Chair, Brigham & Women's Hospital, Boston, Massachusetts. <sup>3</sup>Panel Vice-chair, Mayo Clinic, Phoenix, Arizona. <sup>4</sup>NYU Center for Musculoskeletal Care, New York, New York. <sup>5</sup>Warwick Valley Orthopedic Surgery, Warwick, New York, American Academy of Orthopaedic Surgeons. <sup>6</sup>Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. <sup>7</sup>Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. <sup>8</sup>Bone, Spine and Hand Surgery, Chartered, Brick, NJ, American Academy of Orthopaedic Surgeons. <sup>9</sup>Mount Sinai School of Medicine, New York, New York, American Association of Neurological Surgeons/Congress of Neurological Surgeons. <sup>10</sup>University of California Los Angeles Medical Center, Los Angeles, California, American Association of Neurological Surgeons/Congress of Neurological Surgeons. <sup>11</sup>Penn State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania. <sup>12</sup>Emory University, Atlanta, Georgia, American Association of Neurological Surgeons/Congress of Neurological Surgeons. <sup>13</sup>Long Island Jewish Medical Center, New Hyde Park, New York, Society of Nuclear Medicine. <sup>14</sup>Mayo Clinic, Phoenix, Arizona. <sup>15</sup>University of Wisconsin Hospital, Madison, Wisconsin. <sup>16</sup>Tufts Medical Center, Boston, Massachusetts. <sup>17</sup>Thomas Jefferson University, Philadelphia, Pennsylvania.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

pathological fracture. CT is also preferred over MRI for detecting a characteristic central nidus in patients with suspected osteoid osteoma on radiographs [1,2,18,19].

### **Positron Emission Tomography**

Positron emission tomography (PET) scanning has been used with success for detecting metabolically active metastatic lesions or recurrences and for preoperative evaluation of known sarcomas. Data can be co-registered with CT or MRI to correlate with anatomic information. PET has shown promise in helping differentiate benign from malignant bone lesions [20-25]. However, although studies have found significant differences in the average maximum standard uptake value ( $SUV_{max}$ ) between benign and malignant groups, there is significant overlap in individual tumor types, reflecting variegated metabolic activity in different lesions and complicating myxoid and necrotic components with low metabolic activity [20]. Studies have predominantly been performed on mixed lesion types, with few individual entities that could provide information regarding evaluation of specific tumor types for malignant potential. Bredella et al [21] found that PET with fluorine-18-2-fluoro-2-deoxy-D-glucose tracer (FDG-PET) can help differentiate benign from malignant spinal compression fractures with a sensitivity of 86% and specificity of 83%; however, there was overlap in the range of SUV in the benign and malignant groups. Also, there have been reports of nontumor conditions (especially inflammatory entities) that can also result in abnormal uptake.

The role of PET scanning in the workup of bone tumors has yet to be established. A lesion with indeterminate aggressiveness on radiographs with little to no increased uptake on PET scan could potentially undergo more conservative follow-up; however, more research is required in this regard. It seems clear that PET can provide more information, especially in patients who cannot undergo MRI and in situations where biopsy is not feasible due to location or patient condition. It can also be used to help plan biopsy, with PET/CT fusion images used to target areas with more cellular metabolic activity that may give higher diagnostic yield.

### **Ultrasound**

Although focused musculoskeletal ultrasound (US) with Doppler flow analysis can be a useful tool with some primary osseous and soft-tissue tumors, it is not considered a first-line modality. It should be considered when the size of the lesion renders imaging with pre-contrast-enhanced and post-contrast-enhanced MRI incomplete or when assessment of echotexture and vascularity might decrease the size of the differential after complete assessment with MRI and CT. However, such a US assessment requires a skilled sonographer, and there is little in the medical literature describing differentiating characteristics of musculoskeletal tumors on US.

### **Angiography**

Angiography is not generally indicated except in specialized individual circumstances. Information from invasive diagnostic procedures (except biopsy) has been effectively replaced by noninvasive advanced imaging techniques.

### **Evaluation of Lytic Lesions Versus Lesions With Sclerotic Features**

Lesions seen on radiographs may require additional characterization using advanced imaging examinations; the next appropriate examination may depend on the nature of the lesion: lytic versus sclerotic. For example, a purely lytic lesion may need to be further characterized as solid or cystic not only to narrow the differential diagnosis but also to help guide treatment and biopsy planning (ie, to avoid necrotic or myxoid areas). In this case MRI may be most useful. For mixed lytic/sclerotic or sclerotic lesions there may be matrix mineralization better characterized on CT. Or, if purely sclerotic the differential may be a bone island versus an osteoblastic tumor, in which case a bone scan may be the most useful test.

### **Chondroid Lesions**

There are special considerations when dealing with a suspected chondroid lesion. Intramedullary chondroid lesions appearing in the hands and feet are nearly always benign and may present incidentally or as a pathological fracture. If the lesion is elsewhere it may be challenging to differentiate a benign lesion from a low-grade malignancy using any imaging modality. If there is pain related to the lesion, suspicion of malignancy should be high. However, care should be taken to exclude adjacent joint pathology as the source of pain, which may require advanced imaging. A study of 57 patients presenting to an orthopedic oncologist with shoulder pain and a cartilage tumor showed that 82% had shoulder imaging findings that could explain the pain [26]. Once other etiologies for the pain have been excluded, some radiologic findings have been useful in differentiating benign and malignant lesions. Murphey et al [27] suggest that imaging features including deep endosteal scalloping, cortical destruction, soft-tissue mass (on CT or MRI), periosteal reaction (on radiographs), and marked uptake of



radionuclide can be used to distinguish appendicular enchondroma from chondrosarcoma in at least 90% of cases. However, Bui et al [28] suggest that endosteal scalloping is seen in benign lesions. Geirnaerd et al [29] suggest that radiographic signs cannot discriminate reliably between enchondroma and grade 1 chondrosarcoma, but axial location and large size (greater than 5 cm) are the most reliable predictors of malignancy in this setting. Geirnaerd et al [30] suggest that dynamic contrast-enhanced MRI can assist in differentiating benign from malignant chondroid lesions, and Feldman et al [31] suggest that PET may be useful; however, these modalities have not been clearly established for this purpose. Protocol for follow-up of an asymptomatic, incidentally identified lesion has not been scientifically established. Brien and others [32] suggest that the risk of malignant transformation is increased for larger lesions and lesions in the axial skeleton and in the setting of multiple lesions (eg, Ollier disease). They suggest radiographic follow-up for those at higher risk but do not make specific recommendations regarding interval and extent of follow-up.

### **Lesion Presenting With Pathological Fracture**

Benign and malignant lesions can present with pathological fracture. Especially if imaging is delayed, hemorrhage and bone resorption can lead to a more aggressive appearance, making it difficult to assess for benign characteristics. Early imaging is essential to limit this detrimental effect. In this case, MRI can best evaluate for presence of an underlying lesion.

### **“Incidental Lesions” Found on CT or MRI**

On other occasions lesions are incidentally found on advanced imaging studies and are indeterminate for malignancy. Other imaging examinations may be needed depending upon the findings and level of concern (ie, history of cancer elsewhere). Radiographs are generally indicated for a lesion found on MRI, but a lesion suspected on CT may require an MRI or bone scan for further characterization.

### **Symptoms With Negative Radiographs**

There is a wide differential for symptomatic patients who either have negative radiographs or have radiographs with findings that do not explain the pain. This includes injury such as stress fracture, early infection, or radiographically occult tumor. In any case, advanced imaging may be required based on history and degree of clinical concern. In this situation the referring physician should not be confident that there is no pathology if the radiographic result is negative or nonspecific; radiographs are often insensitive, especially in early disease.

Although CT may be performed in this setting, a radionuclide bone scan may be more useful to localize the abnormality [2,19]. MRI can be very useful in this setting not only to identify whether a lesion is present but also to define the nature of a lesion based on the features discussed above; as a result, MRI is generally preferred. If an osteoid osteoma is suspected, Assoun et al [2] reported that CT was more accurate than MRI in 63% of cases. However, Liu et al [33] reported that dynamic contrast-enhanced MRI can improve conspicuity of osteoid osteoma compared to CT. MRI is useful for determining tissue characteristics of a bone lesion, such as fat, hemorrhage, fibrous tissue, or fluid levels. With gadolinium contrast, cystic or necrotic areas can be detected [9,34-37].

### **Summary**

- Routine radiographs remain the optimal screening technique for primary bone tumors.
- When lesions are characteristically nonaggressive, additional imaging may not be required unless needed for preoperative planning. The data suggest that MRI is the preferred technique for staging of primary bone neoplasms, but CT is equal or superior to MRI in some categories.
- CT is preferred for patients with suspected osteoid osteoma or subtle cortical abnormalities, and for evaluating matrix mineralization.
- Advanced imaging modalities provide complementary information and often more than one modality is required for diagnostic or preprocedure evaluation.

### **Anticipated Exceptions**

Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (i.e., <30 mL/min/1.73m<sup>2</sup>), and almost never in other patients. There is growing literature regarding NSF. Although some

controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates <30 mL/min/1.73m<sup>2</sup>. For more information, please see the [ACR Manual on Contrast Media](#) [38].

## Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
⊕	<0.1 mSv	<0.03 mSv
⊕ ⊕	0.1-1 mSv	0.03-0.3 mSv
⊕ ⊕ ⊕	1-10 mSv	0.3-3 mSv
⊕ ⊕ ⊕ ⊕	10-30 mSv	3-10 mSv
⊕ ⊕ ⊕ ⊕ ⊕	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.		

## Supporting Documents

- [ACR Appropriateness Criteria® Overview](#)
- [Procedure Information](#)
- [Evidence Table](#)

## References

1. Sundaram M, McLeod RA. MR imaging of tumor and tumorlike lesions of bone and soft tissue. *AJR Am J Roentgenol.* 1990;155(4):817-824.
2. Assoun J, Richardi G, Railhac JJ, et al. Osteoid osteoma: MR imaging versus CT. *Radiology.* 1994;191(1):217-223.
3. Zimmer WD, Berquist TH, McLeod RA, et al. Bone tumors: magnetic resonance imaging versus computed tomography. *Radiology.* 1985;155(3):709-718.
4. Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. *AJR Am J Roentgenol.* 1990;155(5):1043-1048.
5. Bloem JL, Taminiau AH, Eulderink F, Hermans J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. *Radiology.* 1988;169(3):805-810.
6. Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. MRI or CT in the preoperative diagnosis of bone tumours. *Eur J Surg Oncol.* 1992;18(1):67-72.

7. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. *Radiology*. 1997;202(1):237-246.
8. Griffiths HJ, Galloway HR, Thompson RC, Jr., et al. The use of MRI in the diagnosis of benign and malignant bone and soft tissue tumours. *Australas Radiol*. 1993;37(1):35-39.
9. Seeger LL, Widoff BE, Bassett LW, Rosen G, Eckardt JJ. Preoperative evaluation of osteosarcoma: value of gadopentetate dimeglumine-enhanced MR imaging. *AJR Am J Roentgenol*. 1991;157(2):347-351.
10. Lang P, Grampp S, Vahlensieck M, et al. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. *AJR Am J Roentgenol*. 1995;165(1):135-142.
11. Swan JS, Grist TM, Sproat IA, Heiner JP, Wiersma SR, Heisey DM. Musculoskeletal neoplasms: preoperative evaluation with MR angiography. *Radiology*. 1995;194(2):519-524.
12. Verstraete KL, De Deene Y, Roels H, Dierick A, Uyttendaele D, Kunnen M. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion. *Radiology*. 1994;192(3):835-843.
13. Feydy A, Anract P, Tomeno B, Chevrot A, Drape JL. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. *Radiology*. 2006;238(2):611-621.
14. Fayad LM, Wang X, Salibi N, et al. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. *AJR Am J Roentgenol*. 2010;195(1):W69-75.
15. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo <sup>1</sup>H MR spectroscopy: initial results. *Radiology*. 2004;232(2):599-605.
16. Collins MS, Koyama T, Swee RG, Inwards CY. Clear cell chondrosarcoma: radiographic, computed tomographic, and magnetic resonance findings in 34 patients with pathologic correlation. *Skeletal Radiol*. 2003;32(12):687-694.
17. Niitsu M, Takeda T. Solitary hot spots in the ribs on bone scan: value of thin-section reformatted computed tomography to exclude radiography-negative fractures. *J Comput Assist Tomogr*. 2003;27(4):469-474.
18. Davies M, Cassar-Pullicino VN, Davies AM, McCall IW, Tyrrell PN. The diagnostic accuracy of MR imaging in osteoid osteoma. *Skeletal Radiol*. 2002;31(10):559-569.
19. Klein MH, Shankman S. Osteoid osteoma: radiologic and pathologic correlation. *Skeletal Radiol*. 1992;21(1):23-31.
20. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. *Radiology*. 2001;219(3):774-777.
21. Bredella MA, Essary B, Torriani M, Ouellette HA, Palmer WE. Use of FDG-PET in differentiating benign from malignant compression fractures. *Skeletal Radiol*. 2008;37(5):405-413.
22. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. *Radiology*. 1996;200(1):243-247.
23. Lee FY, Yu J, Chang SS, Fawwaz R, Parisien MV. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. *J Bone Joint Surg Am*. 2004;86-A(12):2677-2685.
24. Shin DS, Shon OJ, Byun SJ, Choi JH, Chun KA, Cho IH. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. *Skeletal Radiol*. 2008;37(5):415-421.
25. Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. *Ann Nucl Med*. 2008;22(7):603-609.
26. Levy JC, Temple HT, Mollabashy A, Sanders J, Kransdorf M. The causes of pain in benign solitary enchondromas of the proximal humerus. *Clin Orthop Relat Res*. 2005(431):181-186.
27. Murphey MD, Flemming DJ, Boyea SR, Bojescul JA, Sweet DE, Temple HT. Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features. *Radiographics*. 1998;18(5):1213-1237; quiz 1244-1215.
28. Bui KL, Ilaslan H, Bauer TW, Lietman SA, Joyce MJ, Sundaram M. Cortical scalloping and cortical penetration by small eccentric chondroid lesions in the long tubular bones: not a sign of malignancy? *Skeletal Radiol*. 2009;38(8):791-796.
29. Geirnaerdt MJ, Hogendoorn PC, Bloem JL, Taminiau AH, van der Woude HJ. Cartilaginous tumors: fast contrast-enhanced MR imaging. *Radiology*. 2000;214(2):539-546.
30. Geirnaerdt MJ, Hermans J, Bloem JL, et al. Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma. *AJR Am J Roentgenol*. 1997;169(4):1097-1104.

31. Feldman F, Van Heertum R, Saxena C, Parisien M. 18FDG-PET applications for cartilage neoplasms. *Skeletal Radiol.* 2005;34(7):367-374.
32. Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. *Skeletal Radiol.* 1997;26(6):325-353.
33. Liu PT, Chivers FS, Roberts CC, Schultz CJ, Beauchamp CP. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. *Radiology.* 2003;227(3):691-700.
34. Campbell RS, Grainger AJ, Mangham DC, Beggs I, Teh J, Davies AM. Intraosseous lipoma: report of 35 new cases and a review of the literature. *Skeletal Radiol.* 2003;32(4):209-222.
35. Frick MA, Sundaram M, Unni KK, et al. Imaging findings in desmoplastic fibroma of bone: distinctive T2 characteristics. *AJR Am J Roentgenol.* 2005;184(6):1762-1767.
36. Murphey MD, wan Jaovisidha S, Temple HT, Gannon FH, Jelinek JS, Malawer MM. Telangiectatic osteosarcoma: radiologic-pathologic comparison. *Radiology.* 2003;229(2):545-553.
37. Weatherall PT, Maale GE, Mendelsohn DB, Sherry CS, Erdman WE, Pascoe HR. Chondroblastoma: classic and confusing appearance at MR imaging. *Radiology.* 1994;190(2):467-474.
38. American College of Radiology. *Manual on Contrast Media.* Available at: [http://www.acr.org/~link.aspx?\\_id=29C40D1FE0EC4E5EAB6861BD213793E5&\\_z=z](http://www.acr.org/~link.aspx?_id=29C40D1FE0EC4E5EAB6861BD213793E5&_z=z).

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.